Skip to main content

Table 1 Serum levels of AFP CEA, CA125 and CA19-9 in the study subjects

From: Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

  Gastric cancer(n=149) Benign gastric disease(n=111) Healthy control(n=124) Statistic test
Age (Year) 59.1±11.5 52.9±17.4 53.0±9.6 F=10.129, P=0.000
Gender (Male/Female) 115/34 76/35 72/52 χ 2=11.460, P=0.003
AFP (ng/mL) 3.8±16.8 3.3±18.6 2.4±1.3 F=0.332, P=0.718
CEA (ng/mL) 10.5±27.8 1.9±2.8 1.4±0.9 F=11.889, P=0.000
CA125 (U/mL) 20.1±32.7 11.6±17.5 9.9±7.2 F=7.895, P=0.002
CA19-9 (U/mL) 22.8±39.1 11.4±18.7 9.5±4.7 F=10.169, P=0.000
AFP Positive cases (%) 7 (4.7) 1 (0.9) 1 (0.8) χ 2=4.838, P=0.054
CEA Positive cases (%) 26 (17.4) 2 (1.8) 0 (0.0) χ 2=38.088, P=0.000
CA125 Positive cases (%) 21(14.1) 7 (6.3) 1 (0.8) χ 2=18.934, P=0.000
CA19-9 Positive cases (%) 31(20.8) 9 (8.1) 0 (0.0) χ 2=37.840, P=0.000
Combination Positive Cases (%) 60 (40.3) 14 (12.6) 2 (1.6) χ 2=74.443, P=0.000